DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

Bell reported relationships with the Dementia Australia Research Foundation, GlaxoSmithKline Supported Studies ... Co-authors ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Major companies like pharma giant GlaxoSmithKline (GSK) have established their largest ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the ...

Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...